Lumos Diagnostics (ASX:LDX) has been awarded placement of their novel point-of-care test, FebriDx, on the MediGroup national contract, making it available to all their members in the United States.
FebriDx is a rapid point-of-care respiratory test that delivers results in 10 minutes from a fingerstick blood sample.
In July 2023, the US FDA cleared FebriDx to be marketed in the US to diagnose bacterial acute respiratory infection and differentiation from non-bacterial etiology.
The test has been cleared for use by healthcare professionals with patients presenting in urgent care or emergency care settings. It is intended to be used with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.
MediGroup is the largest non-acute care group purchasing organization in the US.
Lumos CEO and managing director Doug Ward said, “We are very pleased to see FebriDx added to MediGroup’s national contract. As a leading group purchasing organization, MediGroup has more than 30,000 members, including a mix of moderately complex labs and CLIA waived locations. This is a key relationship for us as we continue to build out our distribution coverage for FebriDx.”
